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Reverse-Transcriptase Inhibitors in the Aicardi–Goutières 
Syndrome
To the Editor: The Aicardi–Goutières syndrome 
is a genetic encephalopathy that is associated with 
childhood illness and death. The syndrome is 
hypothesized to be due to misidentification of 
self-derived nucleic acids as nonself and the sub-
sequent induction of a type I interferon–mediated 
response that simulates an antiviral reaction.1 
Endogenous retroelements, mobile genetic ele-
ments that can be transcribed to RNA and then 
to DNA by reverse transcription, constitute 40% 
of the human genome and represent a potential 
source of immunostimulatory nucleic acid in 
patients with this syndrome.2
In a single-center, open-label, pilot study involv-
ing patients with the Aicardi–Goutières syndrome 
(ClinicalTrials.gov number, NCT02363452), we 
administered a combination of three nucleoside 
analogue reverse-transcriptase inhibitors — abaca-
vir, lamivudine, and zidovudine — for 12 months, 
at doses used in children with human immuno-
deficiency virus type 1 (HIV-1) infection. The 
study protocol is available with the full text of 
this letter at NEJM.org. The primary aim was to 
determine the effect of treatment on the inter-
feron score, calculated from the expression of 
six interferon-stimulated genes; higher scores 
indicate greater interferon signaling, and scores 
higher than 2.47 are considered to be abnormal.3 
Interferon status was also determined by mea-
surement of interferon-α protein levels in serum, 
plasma, and cerebrospinal fluid (CSF); the anti-
viral protective capacity (interferon activity) of 
patient serum and CSF; and genomewide se-
quencing of RNA extracted from whole blood. 
Clinical features and cerebral blood flow (mea-
sured by means of arterial spin labeling magnetic 
resonance imaging) were secondary efficacy 
measures.
Eight of 11 patients who were recruited from 
a pool of 68 patients in France known to have 
the syndrome completed the study (Table S2 in the 
Supplementary Appendix, available at NEJM.org). 
Three patients withdrew owing to an inability to 
swallow the volume of the study medication. 
There was an effect of treatment on interferon 
signaling, with the median interferon score 
across all 8 patients falling from 9.66 (interquar-
tile range, 6.51 to 13.23) to 5.33 (interquartile 
range, 2.76 to 10.90) (P<0.001) (Fig. 1A). Inter-
feron-α protein levels in serum and plasma and 
interferon antiviral activity in CSF were also re-
duced with treatment (Table S3 in the Supplemen-
tary Appendix). This effect was greatest among 
the 4 patients with mutations in components of 
the RNase H2 complex (with the median score in 
these 4 patients falling from 8.16 [interquartile 
range, 5.41 to 11.94] to 3.51 [interquartile range, 
2.49 to 5.46]). RNA sequencing indicated a reduc-
tion of global interferon-stimulated gene expres-
sion after 12 months of treatment and a return 
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to pretreatment levels 6 months after discontin-
uation of therapy (Figs. S5 and S6 in the Supple-
mentary Appendix). There was an increase in 
cerebral blood flow during the treatment period 
in 3 of 5 patients with data that could be inter-
preted (Fig. S8 and Table S7 in the Supplemen-
tary Appendix).
These results support the hypothesis that 
HIV-1 reverse-transcriptase therapy can reduce 
interferon signaling in patients with the Aicardi–
Goutières syndrome by inhibition of reverse tran-
scription of endogenous retroelements. Changes 
in interferon signaling and cerebral blood flow 
suggest that treatment could have clinical value, 
perhaps in combination with other therapies 
(e.g., inhibitors of Janus kinase 1 and 2).4 The 
open-label design of the study and small sample 
require that a larger group of patients be evalu-
ated in a controlled clinical trial.
Gillian I. Rice, Ph.D.
University of Manchester
Manchester, United Kingdom
Figure 1. Measures of Interferon Status in Eight Patients Completing 12 Months of Therapy.
Panel A shows the interferon score in blood, with higher scores indicating greater interferon signaling. There were 18 recorded values 
before the screening period, 30 recorded values during the screening period (6 months up to and including day 0), 40 recorded values 
during the 12-month treatment period, and 8 recorded values at month 18 (6 months after the discontinuation of treatment). Red lines 
represent the median values according to time period. The dashed line indicates the mean interferon score of controls plus 2 SD; val-
ues above this line (i.e., >2.47) are considered to be abnormal. Panel B shows a comparison of interferon scores in blood in the 6 months 
before treatment, during the treatment period, and after treatment (at month 18), performed with the use of a nonlinear mixed-effects 
model. Panel C shows the interferon-α protein level in blood, Panel D the interferon score in blood, Panel E the interferon-α protein level 
in cerebrospinal fluid (CSF), and Panel F interferon activity in CSF at the indicated time points. Two patients (Patient 5 and Patient 10) 
did not undergo lumbar puncture. In two other patients (Patient 3 and Patient 4), an insufficient CSF sample was available at day 0, 
month 12, or both for assessment of the interferon-α protein level, interferon activity, or both. The correlation coefficient between the 
interferon-α protein level in blood and the interferon score in blood was 0.704 (P<0.001).
In
te
rf
er
on
 S
co
re
 
40
30
10
20
0
Be
fo
re
Sc
re
en
ing
Sc
re
en
ing
Du
rin
g  
  
Tr
ea
tm
en
t
M
on
th
 18
A
In
te
rf
er
on
 S
co
re
35
25
30
20
15
5
10
0
−5 50 10 15 20
Month
B C
D
In
te
rf
er
on
 S
co
re
40
30
10
20
0
Day
0
Month
12
Month
18
P=0.02
P=0.04
In
te
rf
er
on
-α
 P
ro
te
in
 in
 B
lo
od
 (f
g/
m
l) 10,000
8,000
6,000
4,000
3,000
1,000
2,000
0
Day
0
Month
12
Month
18
P=0.04
F
In
te
rf
er
on
 A
ct
iv
ity
 in
 C
SF
 (I
U
/m
l)
200
150
100
50
0
Day
0
Month
12
E
In
te
rf
er
on
-α
 P
ro
te
in
 in
 C
SF
 (f
g/
m
l)
25,000
20,000
15,000
10,000
5,000
0
Day
0
Month
12
Screening During treatment Mo 18
P<0.001
Model-predicted interferon score
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on February 1, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
Correspondence
n engl j med 379;23 nejm.org December 6, 2018
Candice Meyzer, M.D. 
Naïm Bouazza, Ph.D.
Assistance Publique–Hôpitaux de Paris 
Paris, France
Marie Hully, M.D. 
Nathalie Boddaert, M.D.
Hôpital Necker–Enfants Malades 
Paris, France
Michaela Semeraro, M.D., Ph.D.
Université Paris Descartes 
Paris, France
Leo A.H. Zeef, Ph.D.
University of Manchester 
Manchester, United Kingdom
Flore Rozenberg, M.D., Ph.D.
Université Paris Descartes 
Paris, France
Vincent Bondet, Ph.D. 
Darragh Duffy, Ph.D. 
Alba Llibre, Ph.D.
Institut Pasteur 
Paris, France
Jinmi Baek, M.Sc. 
Mame N. Sambe, B.Sc. 
Elodie Henry, M.Sc. 
Valerie Jolaine, M.Sc.
Assistance Publique–Hôpitaux de Paris 
Paris, France
Christine Barnerias, M.D.
Hôpital Necker–Enfants Malades 
Paris, France
Magalie Barth, M.D.
Centre Hospitalier Universitaire Angers 
Angers, France
Alexandre Belot, M.D., Ph.D.
University of Lyon 
Lyon, France
Claude Cances, M.D.
Centre Hospitalier Universitaire Toulouse 
Toulouse, France
François-Guillaume Debray, M.D., Ph.D.
University of Liège 
Liège, Belgium
Diane Doummar, M.D.
Hôpital Armand Trousseau 
Paris, France
Marie-Louise Frémond, M.D. 
Naoki Kitabayashi, B.Sc. 
Alice Lepelley, Ph.D.
Institut Imagine 
Paris, France
Virginie Levrat, M.D.
Centre Hospitalier Annecy Genevois 
Pringy, France
Isabelle Melki, M.D., Ph.D.
Hôpital Robert Debré 
Paris, France
Pierre Meyer, M.D.
Université de Montpellier 
Montpellier, France
Marie-Christine Nougues, M.D.
Hôpital Armand Trousseau 
Paris, France
Florence Renaldo, M.D.
Hôpital Robert Debré 
Paris, France
Mathieu P. Rodero, Ph.D.
Institut Imagine 
Paris, France
Diana Rodriguez, M.D., Ph.D.
Sorbonne Université 
Paris, France
Agathe Roubertie, M.D., Ph.D.
Centre Hospitalier Universitaire de Montpellier 
Montpellier, France
Luis Seabra, M.Sc.
Institut Imagine 
Paris, France
Carolina Uggenti, Ph.D.
University of Edinburgh 
Edinburgh, United Kingdom
Hendy Abdoul, M.D., Ph.D. 
Jean-Marc Treluyer, M.D.
Assistance Publique–Hôpitaux de Paris 
Paris, France
Isabelle Desguerre, M.D. 
Stéphane Blanche, M.D.
Hôpital Necker–Enfants Malades 
Paris, France
Yanick J. Crow, M.D., Ph.D.
University of Edinburgh 
Edinburgh, United Kingdom 
yanickcrow@mac.com
Supported by grants from the European Leukodystrophy Asso-
ciation (ELA 2012-008l1), the European Research Council (GA 
309449 and 786142-E-T1IFNs), ERA-NET Neuron (MR/M501803/1), 
and the French National Research Agency (ANR-10-IAHU-01 and 
CE17001002). Medications were provided by GlaxoSmithKline 
and ViiV Healthcare.
Disclosure forms provided by the authors are available with 
the full text of this letter at NEJM.org.
1. Crow YJ, Manel N. Aicardi-Goutières syndrome and the type I 
interferonopathies. Nat Rev Immunol 2015; 15: 429-40.
2. Volkman HE, Stetson DB. The enemy within: endogenous 
retroelements and autoimmune disease. Nat Immunol 2014; 15: 
415-22.
3. Rice GI, Forte GM, Szynkiewicz M, et al. Assessment of 
interferon-related biomarkers in Aicardi-Goutières syndrome 
associated with mutations in TREX1, RNASEH2A, RNASEH2B, 
RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet 
Neurol 2013; 12: 1159-69.
4. Kothur K, Bandodkar S, Chu S, et al. An open-label trial of 
JAK 1/2 blockade in progressive IFIH1-associated neuroinflam-
mation. Neurology 2018; 90: 289-91.
DOI: 10.1056/NEJMc1810983
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on February 1, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
